Grifols (LTS:0RDV) Ending Cash Position : €0 Mil (As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Grifols Ending Cash Position?

Grifols's Ending Cash Position for the quarter that ended in Dec. 2024 was €0 Mil.

Grifols's annual Ending Cash Position declined from Dec. 2022 (€549 Mil) to Dec. 2023 (€530 Mil) but then increased from Dec. 2023 (€530 Mil) to Dec. 2024 (€980 Mil).

Grifols Ending Cash Position Historical Data

The historical data trend for Grifols's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Ending Cash Position Chart

Grifols Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

Get a 7-Day Free Trial

579.65

2,675.61

549.21

529.58

979.78

Grifols Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23	Jun24	Sep24	Dec24
Ending Cash Position	Get a 7-Day Free Trial															-	-	-	-	-

Grifols Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Grifols's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	529.577	+	450.203
	=	980

Grifols's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	0	+	0
	=	0

Grifols Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Grifols's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Grifols Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (LTS:0RDV) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

GIKLY:USA GIFOF:USA GIFLF:USA GRFS:USA 1GRF:Italy GRFe:UK GRFPe:UK 0RDU:UK GRF.P:Spain GRF:Spain OZTA:Germany GRF:Austria

Address

Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174

Website

https://www.grifols.com

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Grifols Headlines

No Headlines